Monthly Archives: June 2023

Innovation on the horizon: how big pharma investment is driving the development of oligonucleotide-based medicines

The mission of the OLIGOFATSX project is to develop oligonucleotide-based medicines to improve the quality of life of patients affected by rare diseases for which there is still no solution. The scientists involved in the project firmly believe that the future of personalised precision medicine lies in the successful combination of different technologies, including oligonucleotides; […]

Enzymes: key molecules for the development of oligonucleotides

The OLIGOFASTX team is focused on the development of oligonucleotide-based therapies for certain rare diseases covering the whole cycle: from research to manufacturing and distribution of future new oligonucleotide-based drugs. To this end, the companies that make up the consortium are specialised in one area, which in combination provides a form of collaboration that allows […]

From research to the public: the importance of clear and accessible science communication

Clear and accessible science communication is essential to bring research advances closer to the general public and to foster understanding and interest in science. In this blog, we will explore the importance of effective communication in science and how it can improve the dissemination of research results. According to a study by Nature, only a […]

Nanotechnology: a key tool for developing new drugs

Nanotechnology is a field that has revolutionised the pharmaceutical industry. The ability to manipulate materials on a scale as tiny as nanometres allows scientists to create drug delivery systems that make them more effective in treating disease and safer for the patient. In fact, it is a strategic technology for OLIGOFASTX, a consortium which, although […]